Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy

Journal of Clinical Pharmacology

Volumn 42, Issue 5, 2002, Pages 501-511

  Bernstein, Steven H ^a   Jusko, William J ^b   Krzyzanski, Wojciech ^b   Nichol, Janet ^c   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; MEGAKARYOPOIESIS; MODEL; PHARMACODYNAMICS; PREDICTION; QUANTITATIVE ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELL COUNT; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MEGAKARYOCYTES; MIDDLE AGED; THROMBOPOIETIN; TIME FACTORS;

EID: 0036231745     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011553     Document Type: Article

References (36)

1. Thrombopoietin: Understanding and manipulating platelet production
2. Thrombopoietin
3. Megakaryocyte growth and development factor: Analysis of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia
4. Human thrombopoietin levels are high when thromboyctopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction
5. Serum thrombopoietin levels in cyclic thrombocytopenia
6. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production
7. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor transplantation
8. The reciprocal relationship of thrombopoietin (c-mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit
9. The mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets
10. Metabolism of thrombopoietin (TPO) in vivo: Determination of the binding dynamics for TPO in mice
11. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MDGF in megakaryocyte development
12. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver
13. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization
14. Human platelets as a model for the binding and degradation of thrombopoietin
15. Constitutive expression of mpl ligand transcripts during thrombocytopenia or thrombocytosis
16. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets
17. Serum thrombopoietin levels in patients with aplastic anaemia
18. A program package for simulation and parameter estimation in pharmacokinetic systems
19. Human platelets display high-affinity receptors for thrombopoietin
20. Binding and regulation of thrombopoietin to human megakaryocytes
21. Origin of platelet-derived growth factor in megakaryocytes in guinea pigs
22. Thrombokinetics in man
23. Megakaryocytopoiesis: The megakaryocyte/platelet haemostatic axis
24. Kinetics of the formed elements of human blood
25. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement
26. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
27. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers
28. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts
29. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells
30. Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis and expansion of CD34+ progenitor cells from single CD34+ Thy-1+ Lin-primitive progenitor cells
31. Growth factors affecting human thrombocytopoiesis: Potential agents for the treatment of thrombocytopenia
32. Thrombocytopenia in c-mpl-deficient mice
33. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
34. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization
35. Murine thrombopoietin mRNA levels are modulated by platelet count
36. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition